#USA #St. Louis #Panome Bio #Exposomics #Chemical Exposure

Panome Bio Launches Exposomics Services to Measure Chemical Drivers of Human Disease

In a significant advancement for health research, Panome Bio has introduced a cutting-edge exposomics platform designed to measure the chemical drivers behind human diseases. As a prominent multi-omics contract research organization, Panome Bio's new service is the first of its kind commercially available, providing researchers with comprehensive, unbiased chemical exposure profiling in biological samples.

The exposomics offering combines two innovative workflows. The Discovery Exposomics™ service screens over 32,000 chemical compounds, while the Targeted Exposomics™ service delivers precise quantification of 235 high-priority chemicals at an incredibly sensitive picogram-per-milliliter level. This dual approach makes it possible to create detailed environmental exposure profiles—critical for understanding the role of chemical exposures in chronic disease risk, which accounts for approximately 70-90% of such cases.

Historically, environmental exposures have been one of the least measured determinants of health outcomes, with genomic data alone unable to fully explain variability in disease development, manifestation, and progression. As Gary J. Patti, PhD, Chief Scientific Officer at Panome Bio and a professor at Washington University in St. Louis, emphasizes, "Profiling chemical exposures with broad coverage is among the most challenging of the omics sciences."

The complexity of chemical exposures is immense, as numerous synthetic and naturally occurring compounds can enter the body through various channels such as air, water, food, and consumer products. Different compounds vary in their concentrations, persistence, and biological impacts, making the need for a specialized measurement platform paramount. Panome Bio's Discovery Exposomics utilizes MassID™, a proprietary computational engine that analyzes untargeted LC/MS data, alongside a comprehensive database of 32,000 compounds for broad exposure assessments.

Moreover, the Targeted Exposomics service enhances this capability by allowing for the absolute quantification of priority chemicals within a CLIA laboratory setting, using calibrated reference standards. This methodological innovation holds substantial implications for the pharmaceutical industry as inter-patient variability in drug responses is a persistent obstacle in clinical trials, potentially influenced by unmeasured chemical exposures.

As Edward Weinstein, CEO and Co-founder of Panome Bio, points out, “In drug development, we invest enormous resources understanding the genome and the proteome, but we've largely been blind to the chemical environment patients carry with them.” The exposomics platform allows researchers to stratify patients and explain variability in their responses to treatments, ultimately leading to more effective drug development and clinical trial design.

Additionally, the applications of the exposomics service are vast, covering areas such as neurodegeneration, cancer risk assessment, metabolic diseases, autoimmune conditions, reproductive health, and even environmental justice. Researchers can integrate this service seamlessly with Panome Bio's existing capabilities in metabolomics, proteomics, and transcriptomics, establishing financial outcomes tied directly to environmental exposure.

The Exposomics service is currently available for partners in biopharma, biotech, and academia, making it a potentially transformative resource for improving health outcomes through environmental chemistry understanding. Interested parties can find further information and explore collaboration opportunities at www.exposomics.com.

In conclusion, Panome Bio's exposomics platform signifies a substantial leap forward in health research, bridging the gap between chemical exposure measurement and its direct implications on disease processes. This service not only opens new avenues for scientific discovery but also enhances the understanding of how these exposures affect patient outcomes in clinical settings.